Illumina Inc, San Diego, and Partners HealthCare, Boston, have formed a strategic alliance to offer medical geneticists and pathologists infrastructure and networking tools to support the interpretation and reporting process for genetic sequencing data. The tools will integrate the functionality of Illumina’s MiSeq® sequencing system and Partners GeneInsight Suite®, an IT platform that streamlines the analysis, interpretation, and reporting of complex genetic test results. The GeneInsight Suite is registered with the FDA as a Class I exempt medical device.
The new tools will link to Illumina’s BaseSpace cloud computing platform and the MyGenome app for iPad®, as well as to a clinical lab’s local laboratory information system (LIS). The solution creates a seamless workflow, starting on the MiSeq and delivering results directly into the GeneInsight tool, allowing laboratory personnel to interpret data accurately and with confidence. Illumina and Partners HealthCare will initially release the combined MiSeq-GeneInsight solution to a limited number of pilot customers in the clinical testing space.
Today, Illumina also announced the launch of TruSight™ content sets for targeted sequencing, designed for use in next-generation sequencing. The combination of the content sets and new interpretation and reporting tools is a major step forward in realizing the benefits of next generation sequencing. Illumina remains on track to submit the MiSeq system to the U.S. Food and Drug Administration (FDA) for 510(k) clearance before year end.
